GlobeNewswire
-
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
09/03/2026 -
BeautyHealth Expands Skin Health Ecosystem with Growing Adoption of SkinStylus Nano-Channeling, a Popular Pairing with Hydrafacial Treatments
09/03/2026 -
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
09/03/2026 -
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
09/03/2026 -
First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
09/03/2026 -
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
09/03/2026 -
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
09/03/2026 -
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026
09/03/2026 -
Sequel Brings twiist™ Nationwide, Redefining Automated Insulin Delivery Category with Industry-First Innovation
09/03/2026 -
HNL Lab Medicine’s Career Connections Program Builds the Next Generation of Clinical Laboratory Professionals
09/03/2026 -
CenTrak Showcases Next Generation of AI-Enhanced Location Intelligence Platform at HIMSS 2026
09/03/2026 -
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
09/03/2026 -
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
09/03/2026 -
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
09/03/2026 -
Cloudcure Launches Companion App to Close Clinical Adherence Gap in Metabolic Health
09/03/2026 -
SafeSpace Global Opens Nashville Office, Builds Operational Infrastructure to Support Revenue Growth
09/03/2026 -
AsymBio Completes its Dual-Site, One-Center Network with Fengxian Commercial Manufacturing Site Operational, Enhancing End-to-End Biologics CDMO Capabilities
09/03/2026 -
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
09/03/2026 -
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
09/03/2026
Pages